Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma

Marco Pizzi, Matteo Fassan, Stefano Realdon, Mariangela Balistreri, Giorgio Battaglia, Cinzia Giacometti, Giovanni Zaninotto, Vittorina Zagonel, Michele De Boni, Massimo Rugge

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Barrett esophagus is the precancerous lesion leading to Barrett adenocarcinoma. The natural history of Barrett metaplasia and its neoplastic progression are still controversial. Anterior gradient 2 is up-regulated in both Barrett intestinal metaplasia and Barrett adenocarcinoma, but no information is available on anterior gradient 2 expression in the spectrum of the phenotypic changes occurring in the natural history of Barrett adenocarcinoma (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia [formerly called low-grade dysplasia], and high-grade intraepithelial neoplasia [formerly called high-grade dysplasia]). Applying immunohistochemistry and reverse transcription and quantitative real-time polymerase chain reaction, this study addressed the role of anterior gradient 2 in Barrett carcinogenesis. Anterior gradient 2 expression was assessed semiquantitatively in 125 consecutive biopsy samples in the adenocarcinoma spectrum arising in Barrett esophagus (Barrett esophagus cardiac-type metaplasia, 25; Barrett esophagus intestinal metaplasia, 25; low-grade intraepithelial neoplasia, 25; high-grade intraepithelial neoplasia, 25; Barrett adenocarcinoma, 25). Additional biopsy samples of esophageal squamous mucosa (n = 25) served as controls. Anterior gradient 2 messenger RNA expression was also tested (reverse transcription and quantitative real-time polymerase chain reaction) in a different series of 40 samples (esophageal squamous mucosa, 10; Barrett esophagus cardiac-type metaplasia, 10; Barrett esophagus intestinal metaplasia, 10; Barrett adenocarcinoma, 10). Anterior gradient 2 was never expressed in squamous esophageal epithelium but consistently overexpressed (to much the same degree) in the whole spectrum of Barrett disease (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and Barrett adenocarcinoma). Anterior gradient 2 messenger RNA was expressed significantly more in Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, and Barrett adenocarcinoma than in native squamous epithelium (P

Original languageEnglish
Pages (from-to)1839-1844
Number of pages6
JournalHuman Pathology
Volume43
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Barrett Esophagus
Adenocarcinoma
Metaplasia
Neoplasms
Reverse Transcription
Real-Time Polymerase Chain Reaction
Epithelium
Biopsy
Messenger RNA
Natural History

Keywords

  • AGR2
  • Barrett esophagus
  • Esophageal adenocarcinoma
  • Intestinal metaplasia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Pizzi, M., Fassan, M., Realdon, S., Balistreri, M., Battaglia, G., Giacometti, C., ... Rugge, M. (2012). Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. Human Pathology, 43(11), 1839-1844. https://doi.org/10.1016/j.humpath.2012.01.004

Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. / Pizzi, Marco; Fassan, Matteo; Realdon, Stefano; Balistreri, Mariangela; Battaglia, Giorgio; Giacometti, Cinzia; Zaninotto, Giovanni; Zagonel, Vittorina; De Boni, Michele; Rugge, Massimo.

In: Human Pathology, Vol. 43, No. 11, 11.2012, p. 1839-1844.

Research output: Contribution to journalArticle

Pizzi, M, Fassan, M, Realdon, S, Balistreri, M, Battaglia, G, Giacometti, C, Zaninotto, G, Zagonel, V, De Boni, M & Rugge, M 2012, 'Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma', Human Pathology, vol. 43, no. 11, pp. 1839-1844. https://doi.org/10.1016/j.humpath.2012.01.004
Pizzi, Marco ; Fassan, Matteo ; Realdon, Stefano ; Balistreri, Mariangela ; Battaglia, Giorgio ; Giacometti, Cinzia ; Zaninotto, Giovanni ; Zagonel, Vittorina ; De Boni, Michele ; Rugge, Massimo. / Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. In: Human Pathology. 2012 ; Vol. 43, No. 11. pp. 1839-1844.
@article{ed3bfd9159ba42ccb751c43fabe1e91c,
title = "Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma",
abstract = "Barrett esophagus is the precancerous lesion leading to Barrett adenocarcinoma. The natural history of Barrett metaplasia and its neoplastic progression are still controversial. Anterior gradient 2 is up-regulated in both Barrett intestinal metaplasia and Barrett adenocarcinoma, but no information is available on anterior gradient 2 expression in the spectrum of the phenotypic changes occurring in the natural history of Barrett adenocarcinoma (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia [formerly called low-grade dysplasia], and high-grade intraepithelial neoplasia [formerly called high-grade dysplasia]). Applying immunohistochemistry and reverse transcription and quantitative real-time polymerase chain reaction, this study addressed the role of anterior gradient 2 in Barrett carcinogenesis. Anterior gradient 2 expression was assessed semiquantitatively in 125 consecutive biopsy samples in the adenocarcinoma spectrum arising in Barrett esophagus (Barrett esophagus cardiac-type metaplasia, 25; Barrett esophagus intestinal metaplasia, 25; low-grade intraepithelial neoplasia, 25; high-grade intraepithelial neoplasia, 25; Barrett adenocarcinoma, 25). Additional biopsy samples of esophageal squamous mucosa (n = 25) served as controls. Anterior gradient 2 messenger RNA expression was also tested (reverse transcription and quantitative real-time polymerase chain reaction) in a different series of 40 samples (esophageal squamous mucosa, 10; Barrett esophagus cardiac-type metaplasia, 10; Barrett esophagus intestinal metaplasia, 10; Barrett adenocarcinoma, 10). Anterior gradient 2 was never expressed in squamous esophageal epithelium but consistently overexpressed (to much the same degree) in the whole spectrum of Barrett disease (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and Barrett adenocarcinoma). Anterior gradient 2 messenger RNA was expressed significantly more in Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, and Barrett adenocarcinoma than in native squamous epithelium (P",
keywords = "AGR2, Barrett esophagus, Esophageal adenocarcinoma, Intestinal metaplasia",
author = "Marco Pizzi and Matteo Fassan and Stefano Realdon and Mariangela Balistreri and Giorgio Battaglia and Cinzia Giacometti and Giovanni Zaninotto and Vittorina Zagonel and {De Boni}, Michele and Massimo Rugge",
year = "2012",
month = "11",
doi = "10.1016/j.humpath.2012.01.004",
language = "English",
volume = "43",
pages = "1839--1844",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma

AU - Pizzi, Marco

AU - Fassan, Matteo

AU - Realdon, Stefano

AU - Balistreri, Mariangela

AU - Battaglia, Giorgio

AU - Giacometti, Cinzia

AU - Zaninotto, Giovanni

AU - Zagonel, Vittorina

AU - De Boni, Michele

AU - Rugge, Massimo

PY - 2012/11

Y1 - 2012/11

N2 - Barrett esophagus is the precancerous lesion leading to Barrett adenocarcinoma. The natural history of Barrett metaplasia and its neoplastic progression are still controversial. Anterior gradient 2 is up-regulated in both Barrett intestinal metaplasia and Barrett adenocarcinoma, but no information is available on anterior gradient 2 expression in the spectrum of the phenotypic changes occurring in the natural history of Barrett adenocarcinoma (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia [formerly called low-grade dysplasia], and high-grade intraepithelial neoplasia [formerly called high-grade dysplasia]). Applying immunohistochemistry and reverse transcription and quantitative real-time polymerase chain reaction, this study addressed the role of anterior gradient 2 in Barrett carcinogenesis. Anterior gradient 2 expression was assessed semiquantitatively in 125 consecutive biopsy samples in the adenocarcinoma spectrum arising in Barrett esophagus (Barrett esophagus cardiac-type metaplasia, 25; Barrett esophagus intestinal metaplasia, 25; low-grade intraepithelial neoplasia, 25; high-grade intraepithelial neoplasia, 25; Barrett adenocarcinoma, 25). Additional biopsy samples of esophageal squamous mucosa (n = 25) served as controls. Anterior gradient 2 messenger RNA expression was also tested (reverse transcription and quantitative real-time polymerase chain reaction) in a different series of 40 samples (esophageal squamous mucosa, 10; Barrett esophagus cardiac-type metaplasia, 10; Barrett esophagus intestinal metaplasia, 10; Barrett adenocarcinoma, 10). Anterior gradient 2 was never expressed in squamous esophageal epithelium but consistently overexpressed (to much the same degree) in the whole spectrum of Barrett disease (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and Barrett adenocarcinoma). Anterior gradient 2 messenger RNA was expressed significantly more in Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, and Barrett adenocarcinoma than in native squamous epithelium (P

AB - Barrett esophagus is the precancerous lesion leading to Barrett adenocarcinoma. The natural history of Barrett metaplasia and its neoplastic progression are still controversial. Anterior gradient 2 is up-regulated in both Barrett intestinal metaplasia and Barrett adenocarcinoma, but no information is available on anterior gradient 2 expression in the spectrum of the phenotypic changes occurring in the natural history of Barrett adenocarcinoma (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia [formerly called low-grade dysplasia], and high-grade intraepithelial neoplasia [formerly called high-grade dysplasia]). Applying immunohistochemistry and reverse transcription and quantitative real-time polymerase chain reaction, this study addressed the role of anterior gradient 2 in Barrett carcinogenesis. Anterior gradient 2 expression was assessed semiquantitatively in 125 consecutive biopsy samples in the adenocarcinoma spectrum arising in Barrett esophagus (Barrett esophagus cardiac-type metaplasia, 25; Barrett esophagus intestinal metaplasia, 25; low-grade intraepithelial neoplasia, 25; high-grade intraepithelial neoplasia, 25; Barrett adenocarcinoma, 25). Additional biopsy samples of esophageal squamous mucosa (n = 25) served as controls. Anterior gradient 2 messenger RNA expression was also tested (reverse transcription and quantitative real-time polymerase chain reaction) in a different series of 40 samples (esophageal squamous mucosa, 10; Barrett esophagus cardiac-type metaplasia, 10; Barrett esophagus intestinal metaplasia, 10; Barrett adenocarcinoma, 10). Anterior gradient 2 was never expressed in squamous esophageal epithelium but consistently overexpressed (to much the same degree) in the whole spectrum of Barrett disease (Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and Barrett adenocarcinoma). Anterior gradient 2 messenger RNA was expressed significantly more in Barrett esophagus cardiac-type metaplasia, Barrett esophagus intestinal metaplasia, and Barrett adenocarcinoma than in native squamous epithelium (P

KW - AGR2

KW - Barrett esophagus

KW - Esophageal adenocarcinoma

KW - Intestinal metaplasia

UR - http://www.scopus.com/inward/record.url?scp=84867882327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867882327&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.01.004

DO - 10.1016/j.humpath.2012.01.004

M3 - Article

VL - 43

SP - 1839

EP - 1844

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -